SAM
ALNY icon

Senzar Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Senzar Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-5,425
Closed -$534K – 1
2018
Q2 		$534K Buy
+5,425
New +$538K 1.54% 16

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Senzar Asset Management's ALNY Position: Q3 2018 in Review

Senzar Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2018, closing a stake of 5,425 shares — an estimated $534K sold.

Senzar Asset Management first reported a position in ALNY in Q2 2018 and held it in 1 quarter. The position peaked at $534K in Q2 2018. 304 funds tracked by Wall St. Rank hold ALNY as of Q3 2018.

  • Senzar Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Senzar Asset Management sold 5,425 Alnylam Pharmaceuticals shares in Q3 2018, an estimated $534K.
  • Senzar Asset Management first reported a position in Alnylam Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Senzar Asset Management's Alnylam Pharmaceuticals position peaked at $534K in Q2 2018.
  • 304 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2018.

Based on Senzar Asset Management's 13F filing for Q3 2018.